The data showed notable responses, even among patients living with chronic lymphocytic leukemia (CLL) who had previous exposure to B-cell receptor–associated kinase inhibitors, the authors said.

New treatment option for rare, life-altering pediatric brain tumors Less than 10% of new medicine approvals over the past five years have focused ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved revumenib for patients aged 1 year and older with relapsed or refractory acute myeloid leukemia ...

Eli Lilly has agreed to acquire Kelonia Therapeutics for up to $7 billion, in a deal that would bolster the buyer’s oncology ...

Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce that Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, has been registered by the ...

Revuforj is approved for relapsed or refractory acute leukemia with KMT2A translocation in patients aged 1 year and older. The AUGMENT-101 trial showed a 21.2% complete remission rate with a median ...

ZUMA-2 cohorts drive brexu-cel’s journey in relapsed/refractory mantle cell lymphoma, from high response rates to dose ...

The ORR was 69% (95% CI, 61-76) in the zanubrutinib arm and 46% (95% CI, 34-58) in the obinutuzumab monotherapy arm. The Food and Drug Administration (FDA) has granted accelerated approval to Brukinsa ...

Explore how BTK resistance drives poor outcomes in relapsed mantle cell lymphoma and why ZUMA-2 CAR T therapy emerges as a ...

Carvykti is a B-cell maturation antigen-directed genetically modified autologous chimeric antigen receptor T-cell therapy. The Food and Drug Administration (FDA) has approved Carvykti ® ...

Novel targeted therapies for R/R CLL, including venetoclax plus rituximab, acalabrutinib, and zanubrutinib, have favorable safety profiles. Bendamustine plus rituximab showed a lower risk of severe ...